Neoadjuvant Atezolizumab/Epirubicin Plus Trastuzumab/Pertuzumab Shows High pCR Rate in Early HER2+ Breast Cancer
May 12th 2023
Preoperative treatment with atezolizumab, epirubicin, trastuzumab, and pertuzumab led to improved rates of pathologic complete response and decreased residual cancer burden compared with trastuzumab, pertuzumab, and chemotherapy alone in patients with early-stage HER2-positive breast cancer, according to findings from the randomized phase 2 ATHENE trial.